AMKR vs GEN

AMKR demonstrates strong financial health with a Piotroski F-Score of 8/9, indicating robust operational efficiency and profitability trends. The company trades at a forward P/E of 18.15, below the sector average of 77.27, suggesting relative undervaluation despite high growth expectations. Earnings growth of 61% YoY and consistent earnings beats (3/4 in last 4 quarters) reinforce its momentum. However, the absence of an Altman Z-Score and bearish insider activity (4 sales totaling $2.83M) introduce cautionary signals. The intrinsic value of $44.25 exceeds the current price of $41.61, supporting a fair value upside.

GEN presents a stark contrast between strong growth fundamentals and deteriorating financial health and market sentiment. While the Piotroski F-Score of 4/9 indicates a stable but mediocre health profile, the current ratio of 0.47 and high debt-to-equity ratio of 3.63 signal significant short-term liquidity risks. Valuation is highly attractive on a forward basis (Forward P/E 6.40, PEG 0.47), but this is heavily offset by a bearish technical trend (0/100) and insider selling. The stock is currently trading near its 52-week low, suggesting the market is pricing in balance sheet fragility over growth potential.